Adaptimmune Therapeutics Plc Other Current Liabilities

Adaptimmune Therapeutics Plc (ADAP) currently reports a other current liabilities of $22M as of June 2025. That compares with $31M in the prior-year period — down 27.5% year over year. Use the charts on this page to explore Adaptimmune Therapeutics Plc's other current liabilities history and peer comparisons.

Adaptimmune Therapeutics Plc's other current liabilities decreased from $31M to $22M — a 27.5% year-over-year decrease (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adaptimmune Therapeutics Plc reported $22M in other current liabilities as of June 2025. That compares with $31M in the prior-year period — down 27.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $22M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Adaptimmune Therapeutics Plc, and consider following ADAP for alerts when major investors trade the stock.

Adaptimmune Therapeutics Plc is classified in the Healthcare sector. On other current liabilities, it currently shows $22M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ADAP with unrelated industries.